The study was the largest prospective study to date assessing the combination of anti-programmed cell death protein 1 (PD-1) antibodies and multikinase inhibitors. This combination has shown encouraging activity in several tumour types, including colorectal cancer. In this study, 5 of 70 treated patients had a partial response, corresponding to an objective response rate of 7%.
Hannes Buchner, Staburo Managing Director, along with working students Maria Blanco and Tim Müller, will present their applied research project titled “Deriving interpretable thresholds for variable importance in random forests by permutation” at the colloquium of the Statistics Institute at the Ludwig-Maximilians-Universität (LMU) on May 10th at 16:00.
Staburo supported an exploratory analysis of the mRNA-1273 Phase 1 Trial to assess the clinical utility of the quantitative Roche Elecsys® Anti-SARS-CoV-2 S assay (ACOV2S). Geometric mean concentrations as well as seroconversion over time was assessed overall and by dose and age group.
Staburo supported the German pharmaceutical company, Dr. Pfleger Arzneimittel GmbH, Bamberg, during the whole lifecycle of the ‘ipalat® Hydro Med’ study in terms of protocol writing, randomisation, statistical analysis plan writing, statistical programming, report and publication writing.
The results of the so-called VidazaAllo Study – with Universitätsklinikum Hamburg-Eppendorf (UKE) being the sponsor – has been published by the Journal of Clinical Oncology (JCO) on July 20. The key objective of the VidazaAllo Study was: Can allogenic stem cell transplantation (HSCT) in older patients with myelodysplastic syndromes (MDS) improve overall survival in comparison with standard 5-azacytidine (Vidaza) therapy?
BioNTech recognizes employees and partners for their support in developing historic vaccine
We thank BioNTech for recognizing our biostatistics support in the development of a vaccine against COVID-19! We were very happy to add our expertise to this meaningful project and thank the whole team!
A new study in collaboration with Universitätsklinikum Hamburg-Eppendorf (UKE) and CTC North GmbH & Co. KG has been approved by the German Gemeinsamer Bundesausschuss (G-BA) on December 4. The G-BA has commissioned the UKE to research the benefits of allogeneic stem cell transplantation to treat multiple myeloma in relapsed/progressive patients.
On behalf of Staburo, Josef Höfler and our former colleague Nicole Krämer submitted comments on the EMA’s draft guidance on “Points to consider on implications of Coronavirus disease (COVID-19) on methodological aspects of ongoing clinical trials”. The guidance, set...
Staburo Managing Director Dr. Hannes Buchner and our team was involved in statistical consulting and performing data analysis in a trial for a medical device which is now being used in COVID-19 patients. The device binds SARS-CoV-2 and removes it from the blood. It...
Staburo’s Managing Director Josef Höfler prepared and took part in a Scientific Advice meeting at the agency BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) in Bonn.